Pancreatic Cancer Research

ResearcherFox Chase Cancer CenterActive in the last 2 years

Charline Ogier

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4129-0433; OpenAlex author ID A5017056398. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
1
Labs led
0
Collaborators
36
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 grant · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 7

  1. ANO6-mediated trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer cell growth and immune suppression. Co-author DOI 10.1038/s43018-026-01265-5↗
  2. Netrin G1 Ligand is a new stromal immunomodulator that promotes pancreatic cancer Co-author DOI 10.1101/2024.05.15.594354↗
  3. Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling. Co-author DOI 10.1016/j.celrep.2023.113369↗
  4. NetrinG1+ cancer-associated fibroblasts generate unique extracellular vesicles that support the survival of pancreatic cancer cells under nutritional stress. Co-author DOI 10.1158/2767-9764.crc-21-0147↗
  5. Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.08.015↗
  6. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Co-author DOI 10.1002/ijc.32273↗
  7. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical model… Co-author DOI 10.1016/j.canlet.2018.06.023↗

Grants 1

  1. Preclinical Evaluation of Netrin-1 Antibody for Treatment of Pancreatic Cancer AWARD pancan:2021-charline-ogier-phd-preclinical-evaluation-of-netrin-1-antib

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Debora Barbosa Vendramini Costa · 4 shared papers, 2022–2026 · strength 0.60
  2. Ralph A. Francescone III · 4 shared papers, 2020–2026 · strength 0.55
  3. Janusz Franco‐Barraza · 4 shared papers, 2020–2026 · strength 0.55
  4. Edna Cukierman · 4 shared papers, 2020–2026 · strength 0.55
  5. Tiffany Luong · 3 shared papers, 2022–2026 · strength 0.47
  6. Igor A. Astsaturov · 3 shared papers, 2020–2026 · strength 0.40
  7. Linara Gabitova-Cornell · 2 shared papers, 2020–2026 · strength 0.26
  8. Erica A. Golemis · 2 shared papers, 2020–2026 · strength 0.26
  9. Corinne Bousquet · 2 shared papers, 2018–2026 · strength 0.25
  10. Nathaniel W. Snyder · 1 shared paper, 2026 · strength 0.18
  11. Anna C. Lilly · 1 shared paper, 2026 · strength 0.18
  12. Jerome F. Cros · 1 shared paper, 2026 · strength 0.18
  13. Serge Y Fuchs · 1 shared paper, 2026 · strength 0.18
  14. Rolf A. Brekken · 1 shared paper, 2026 · strength 0.18
  15. Nina G. Steele · 1 shared paper, 2024 · strength 0.16
  16. Huamin Wang · 1 shared paper, 2024 · strength 0.16
  17. Christel Larbouret · 2 shared papers, 2018–2019 · strength 0.14
  18. André Pèlegrin · 2 shared papers, 2018–2019 · strength 0.14
  19. Pierre‐Emmanuel Colombo · 2 shared papers, 2018–2019 · strength 0.14
  20. Thierry Chardès · 2 shared papers, 2018–2019 · strength 0.14
  21. Crissy Dudgeon · 1 shared paper, 2023 · strength 0.14
  22. Subhajyoti De · 1 shared paper, 2023 · strength 0.14
  23. Anthony Casabianca · 1 shared paper, 2023 · strength 0.14
  24. Patrick Mehlen · 1 shared paper, 2023 · strength 0.14
  25. Aram F. Hezel · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.